Evidence map›Paper›PMID 29410537›Full record

ArticleScientific reports2018

Spheroid-cultured human umbilical cord-derived mesenchymal stem cells attenuate hepatic ischemia-reperfusion injury in rats.

Yi Sun, Yang Wang, Liang Zhou, Yizhou Zou, Gengwen Huang, Ge Gao, Shi Ting, Xiong Lei, Xiang Ding

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Curcumin in ischemia-reperfusion injury across multiple organs: A review.The Journal of international medical research · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Research progress on optimization ofFrontiers in bioengineering and biotechnology · 2024
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yi SunInstitute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, 410078, China.
Yang WangInstitute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, 410078, China.
Liang ZhouDepartment of Ophthalmology, Second Xiangya Hospital, Central South Univerisity, Changsha, 410011, China.
Yizhou ZouDepartment of Immunology, Xiangya School of Medicine, Central South University, Changsha, 410078, China.
Gengwen HuangDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, 410078, China.
Ge GaoDepartment of Laboratory Medicine, Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Shi TingDepartment of Laboratory Medicine, Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Xiong LeiDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, 410078, China.
Xiang DingDepartment of Organ Transplantation, Xiangya Hospital, Central South University, Changsha, 410078, China. xiangding@csu.edu.cn.ORCID 0000-0002-3613-9835
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cell (MSC) transplantation is a promising treatment for ischemia-reperfusion injury (IRI). However, its effects on hepatic IRI were not consistent in the previous studies. 3D spheroid-cultured MSCs enhance their production of trophic and anti-inflammatory properties, but their effects on hepatic IRI remain unclear. In this study, we compared the 3D spheroid-cultured human umbilical derived MSCs (3D UC-MSCs) with 2D-cultured UC-MSCs (2D UC-MSCs) on treating hepatic IRI. The RNA sequencing data showed that suppression of cell mitosis, response to hypoxia, inflammation, and angiogenesis were the top genetic changes in 3D UC-MSCs compared with 2D UC-MSCs. Although both pro-inflammatory and anti-inflammatory genes were upregulated in the 3D UC-MSCs, the mRNA and protein of an RNase (ZC3H12A), which turnovers the mRNA of pro-inflammatory genes at the post-transcript level, were significantly upregulated in 3D UC-MSCs. 3D UC-MSCs reduced the secretion of many chemokines and growth factors, but increased the secretion of vascular endothelial growth factor. Compared with the vehicle and 2D UC-MSCs, 3D UC-MSCs significantly reduced hepatic IRI in rats, based on the plasma aminotransferase levels, liver damage scores, neutrophil infiltration, hepatocyte apoptosis and expression of inflammation-associated genes. These findings suggest that 3D UC-MSCs therapy is a promising treatment for hepatic IRI.

Indexed as

AnimalsApoptosisChemokinesDisease Models, AnimalHumansInflammationLiverLiver DiseasesMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationRatsRats, Sprague-DawleyReperfusion InjurySpheroids, CellularUmbilical CordChemokines

Identifiers

PMID29410537
PMCPMC5802716
OpenAlexW2807229846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.